← Leaderboards
Donald E Mosier
Scripps Research Institute
$15,768,525
Attributed
$15,768,525
Total exposure
16
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$15,768,525 · 16
By mechanism
R01$8,756,979 · 4
T32$3,222,717 · 1
U19$1,588,891 · 1
R21$1,417,515 · 3
R56$473,750 · 1
P01$265,096 · 2
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- James Alfred Hoch$15,381,289
- Subhash C Sinha$3,568,854
- James C. Paulson$35,883,499
- Mark Jay Yeager$20,690,767
- Bruce Edward Torbett$29,036,384
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1InfectionVirusCellsResearch StudyTransmission ProcessCcr5 GeneVariantBinding (Molecular Function)ProgramsMutatePreventStagingSeriesMicrobicideInhibitor/AntagonistPropertyEventAntiviral AgentsClinical ResearchHiv InfectionsMacrophageLaboratoriesBiological
Grant awards (47)
Modeling HIV-1 primary transmission in vitro and in vivo$741,270
R01 · FY2015 · AI · contact PI
Modeling HIV-1 primary transmission in vitro and in vivo$742,002
R01 · FY2014 · AI · contact PI
Novel Mechanisms for Coreceptor Switching$236,875
R21 · FY2014 · AI · contact PI
Modeling HIV-1 primary transmission in vitro and in vivo$564,523
R01 · FY2013 · AI · contact PI
Novel Mechanisms for Coreceptor Switching$267,195
R21 · FY2013 · AI · contact PI
Modeling HIV-1 primary transmission in vitro and in vivo$495,372
R01 · FY2012 · AI · contact PI
Modeling HIV-1 primary transmission in vitro and in vivo$500,411
R01 · FY2011 · AI · contact PI
HIV Coreceptor Switching$473,750
R56 · FY2011 · AI · contact PI
Defining Inhibitory Mechanisms of Novel CCRS-targeted Microbicide Candidates$531,578
U19 · FY2010 · AI · contact PI
Cross-reactive HERV immunity to combat HIV-1 infection$474,750
R01 · FY2010 · AI · contact PI
HIV Coreceptor Switching$446,760
R01 · FY2010 · AI · contact PI
Defining Inhibitory Mechanisms of Novel CCRS-targeted Microbicide Candidates$524,932
U19 · FY2009 · AI · contact PI
Cross-reactive HERV immunity to combat HIV-1 infection$474,750
R01 · FY2009 · AI · contact PI
HIV Coreceptor Switching$451,272
R01 · FY2009 · AI · contact PI
HIV Coreceptor Switching$300,775
R01 · FY2009 · AI · contact PI
Improved Humanized Mouse Models for Vaccine Development$236,875
R21 · FY2009 · AI · contact PI
Defining Inhibitory Mechanisms of Novel CCRS-targeted Microbicide Candidates$532,381
U19 · FY2008 · AI · contact PI
HIV Coreceptor Switching$451,272
R01 · FY2008 · AI · contact PI
Improved Humanized Mouse Models for Vaccine Development$284,250
R21 · FY2008 · AI · contact PI
HIV Coreceptor Switching$451,272
R01 · FY2007 · AI · contact PI
Immunology Training$432,263
T32 · FY2007 · AI · contact PI
Recombinant CCR5 Inhibitors for Topical Microbicides$161,305
R21 · FY2007 · AI · contact PI
HIV Coreceptor Switching$464,750
R01 · FY2006 · AI · contact PI
Immunology Training$373,949
T32 · FY2006 · AI · contact PI
Recombinant CCR5 Inhibitors for Topical Microbicides$231,015
R21 · FY2006 · AI · contact PI
HIV CORECEPTOR SWITCHING$422,325
R01 · FY2005 · AI
Immunology Training$410,931
T32 · FY2005 · AI
Immunology Training$424,720
T32 · FY2004 · AI
HIV CORECEPTOR SWITCHING$422,325
R01 · FY2004 · AI
Coreceptor usage and HIV disease kinetics$16,216
M01 · FY2004 · RR
HIV CORECEPTOR SWITCHING$422,325
R01 · FY2003 · AI
Immunology Training$415,294
T32 · FY2003 · AI
IMMUNOLOGY TRAINING$421,829
T32 · FY2002 · AI
ADOPTIVE IMMUNE THERAPY IN THE HU-PBL-SCID MODEL$310,275
R01 · FY2002 · AI
CCR5 POLYMORPHISMS AND SUSCEPTIBILITY TO HIV 1 INFECTION$0
M01 · FY2002 · RR
Evaluation of Virus Entry Inhibitors In hu-PBL-SCID Mice$0
P01 · FY2002 · AI
CORECEPTOR USAGE AND HIV DISEASE KINETICS$0
M01 · FY2002 · RR
ADOPTIVE IMMUNE THERAPY IN HU PBL SCID MODEL$0
M01 · FY2002 · RR
IMMUNOLOGY TRAINING$386,099
T32 · FY2001 · AI
ADOPTIVE IMMUNE THERAPY IN THE HU-PBL-SCID MODEL$310,275
R01 · FY2001 · AI
ACTIVITY OF HIV CO-RECEPTOR ANTAGONIST IN HU-PBL-SCID MICE$0
P01 · FY2001 · AI
IMMUNOLOGY TRAINING$357,632
T32 · FY2000 · AI
ADOPTIVE IMMUNE THERAPY IN THE HU-PBL-SCID MODEL$310,275
R01 · FY2000 · AI
ACTIVITY OF HIV CO-RECEPTOR ANTAGONIST IN HU-PBL-SCID MICE$265,096
P01 · FY2000 · AI
ADOPTIVE IMMUNE THERAPY IN HU PBL SCID MODEL$27,361
M01 · FY2000 · RR
CORECEPTOR USAGE AND HIV DISEASE KINETICS$0
M01 · FY2000 · RR
CCR5 POLYMORPHISMS AND SUSCEPTIBILITY TO HIV 1 INFECTION$0
M01 · FY2000 · RR